Benign lung nodules can grow, and that single fact catches many people off guard. The assumption that “growing means cancer” is deeply embedded in how patients and even some clinicians think about lung spots, but the reality is more nuanced. Growth alone does not distinguish a harmless nodule from a dangerous one. What matters more is how fast a nodule grows, what it looks like on imaging, and what caused it in the first place. Most benign nodules either stay the same size or enlarge so slowly that the change is barely measurable over years.
What Causes Benign Lung Nodules
A benign lung nodule is any small spot in the lung, generally three centimeters or less, that is not cancer. The causes fall into a few broad categories, and knowing the cause helps explain whether growth is expected.
Infections are among the most common culprits. A fungal infection like histoplasmosis or a mycobacterial infection like tuberculosis can leave behind a small granuloma, essentially a ball of immune cells that walled off the infection. A large retrospective study of 500 granuloma cases from seven countries found a specific cause in about 58% of them, with mycobacterial and fungal infections accounting for a quarter and sarcoidosis (an inflammatory condition) accounting for another 27%.1Journal of Clinical Pathology. Causes of pulmonary granulomas: a retrospective study of 500 cases from seven countries These granulomas often calcify over time and stop changing, but while the underlying infection or inflammation is still active, they can grow.
Autoimmune and inflammatory diseases also produce nodules. Rheumatoid arthritis, for example, can generate lung nodules made of inflamed tissue that looks nothing like a tumor under a microscope but can mimic one on a scan.2Journal of Pulmonary Medicine & Respiratory Research. Pulmonary Nodules In Patients With Chronic Rheumatoid Arthritis: An Up-To-Date Review These rheumatoid nodules sometimes grow during disease flares and shrink during remission, making their behavior unpredictable on any single scan.
Occupational exposures round out the picture. Workers exposed to silica dust, coal dust, or asbestos fibers over years can develop small rounded nodules scattered through the lungs. In silicosis and coal workers’ pneumoconiosis, these nodules reflect fibrosis rather than tumor growth, and they can slowly enlarge or even merge into larger masses of scarred tissue over decades of continued exposure.3Elsevier. Occupational Lung Disease
Hamartomas and Other Benign Tumors
Not all benign nodules come from infection or inflammation. Some are true benign tumors, and the most common of these is the pulmonary hamartoma. A hamartoma is a disorganized clump of normal tissues, typically cartilage mixed with fat, fibrous tissue, and sometimes smooth muscle, that forms a nodule in the lung. It is two to three times more common in men and usually turns up incidentally on imaging in people in their 50s or 60s.4PubMed Central. Symptomatic Pulmonary Hamartoma Most hamartomas cause no symptoms at all.
Under a microscope, hamartomas have a very recognizable appearance: nodular cartilage proliferation with little pockets of entrapped airway lining, mixed in with fat cells and fibrous tissue.5PubMed Central. The clinicopathological challenges of symptomatic and incidental pulmonary hamartomas diagnosis That jumble of tissue types, with at least two mesenchymal elements plus benign entrapped epithelium, is what pathologists look for when confirming the diagnosis.6American Journal of Clinical Pathology. Clinical, Radiologic, and Pathologic Characteristics of Pulmonary Hamartomas With Uncommon Presentation
The critical point about hamartomas is that they do grow, just very slowly. A study measuring volume doubling times in hamartomas found a median doubling time of roughly 2,000 to 2,250 days, which works out to about six years for the nodule to double in volume. Of 25 hamartomas tracked in that study, 24 had estimated volume doubling times above 600 days, and only 1 fell below 400 days.7PubMed Central. Growth Rates of Pulmonary Carcinoid Tumors and Hamartomas That kind of glacial pace is reassuring, but it also means a hamartoma followed over several years will often look slightly bigger on each scan, which can unsettle patients who expect benign to mean unchanging.8PubMed Central. Pulmonary Hamartomas: A Single-Center Analysis of 59 Cases
How Growth Speed Separates Benign From Malignant
Doctors rely heavily on a concept called volume doubling time to gauge whether a growing nodule is worrisome. Volume doubling time is exactly what it sounds like: how many days it takes for a nodule’s volume to double. Because volume scales with the cube of diameter, a nodule can double in volume with only a modest change in diameter on a flat image, which is why volumetric CT measurements are increasingly preferred over simple diameter readings.
In clinical practice, volume doubling times are often sorted into three bands of suspicion. Doubling times above 600 days are considered the least suspicious, 400 to 600 days raises moderate concern, and anything below 400 days is treated with the highest suspicion for malignancy.9PubMed Central. Volume Doubling Times of Benign and Malignant Nodules in Lung Cancer Screening Research using software-calculated doubling times has used 500 days as the upper boundary for most malignancies when trying to distinguish them from benign solid nodules.10PubMed. Software volumetric evaluation of doubling times for differentiating benign versus malignant pulmonary nodules
The takeaway is straightforward. A nodule that grows measurably within a few months is a red flag. A nodule that barely changes over a year or two leans strongly benign. But those categories overlap. Some low-grade cancers grow just as slowly as a hamartoma, and some active infections can make a nodule swell quickly. Growth speed is a powerful signal, not a definitive one.
What Imaging Can and Cannot Tell You
Calcification patterns are one of the oldest tricks in the book for assessing whether a nodule is benign. Certain patterns, like diffuse calcification throughout the nodule, “popcorn” calcification (classic for hamartomas), or concentric ring-like layers, strongly suggest benign disease.11PubMed Central. Calcified Lung Nodules: A Diagnostic Challenge in Clinical Daily Practice A fully calcified nodule is almost always a healed granuloma that poses no threat.
But the confidence calcification provides has limits. Some calcification patterns overlap between benign and malignant conditions, and cancers can occasionally develop in or around calcified tissue. As one review put it, using calcification as a criterion to determine benign nature “can be misleading.”12PubMed Central. The calcified lung nodule: What does it mean? Eccentric calcification, where the calcium sits off to one side, is the pattern that raises the most concern because it can represent a tumor that has engulfed a pre-existing calcified granuloma.
PET scans, which measure metabolic activity using a radioactive sugar tracer, add another layer of information but have their own blind spots. Inflammatory nodules can light up intensely on a PET scan, mimicking cancer. A case report described a highly metabolically active lung nodule that stayed the same size over four months; the high tracer uptake was ultimately attributed to inflammatory cells, not a tumor.13PubMed. False positive for malignancy of a lung nodule on FDG PET/CT scans–a lesion with high FDG uptake but stable in size Active infections, sarcoidosis, and rheumatoid nodules can all produce false positive PET results. That is why PET findings are always interpreted alongside the growth history and CT appearance, never in isolation.
The Challenge of Measuring Small Changes
One underappreciated complication is how hard it is to measure small nodules accurately. If you scan the same nodule twice on the same day without changing anything, the two measurements will not be identical. Differences in how the patient breathes, slight shifts in position, and the software used to draw the nodule’s boundary all introduce variability.
A study designed to quantify this problem, aptly called a “coffee-break” study, had patients scanned twice in quick succession with no real change expected. The researchers found that the limits of agreement for relative volume difference ranged from roughly minus 16% to plus 15%. In practical terms, a volume change of up to about 15% in either direction on a follow-up scan could be measurement noise rather than real growth.14PubMed Central. Defining growth in small pulmonary nodules using volumetry: results from a “coffee-break” study and implications for current nodule management guidelines Current guidelines generally treat a volume increase under 25% as stability, building in a buffer for that measurement uncertainty. This means that for very small nodules, the question of whether growth has occurred can genuinely be unanswerable on any single follow-up scan.
How Doctors Decide When to Scan Again
The Fleischner Society guidelines are the most widely used framework for managing incidentally discovered lung nodules. Updated in 2017, these guidelines streamlined earlier recommendations by raising the minimum size threshold for routine follow-up, giving broader time ranges for follow-up intervals rather than rigid schedules, and combining recommendations for solid and partially solid nodules into one table.15PubMed. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017
The updated guidelines emphasize several factors beyond raw size. Nodule shape, edge characteristics, location in the lung, and the patient’s personal risk factors for lung cancer all influence whether follow-up imaging is recommended and how soon.16PubMed. Updated Fleischner Society Guidelines for Managing Incidental Pulmonary Nodules: Common Questions and Challenging Scenarios A smooth, round, six-millimeter solid nodule in a person who has never smoked may need no follow-up at all. The same nodule in a long-time smoker with a family history of lung cancer would likely get a repeat scan in six to twelve months.
For nodules found during dedicated lung cancer screening programs rather than incidentally, a separate set of guidelines (Lung-RADS) applies, with its own size and growth thresholds. In a large lung cancer screening cohort of nearly 4,800 patients, about 3% underwent surgical resection of a nodule, and of those who had surgery, roughly 13% turned out to have benign diagnoses.17JTO Clinical and Research Reports. Surgical Resection of Benign Nodules in Lung Cancer Screening: Incidence and Features Those numbers highlight a real tension in nodule management: the system is designed to catch cancers early, which inevitably means some benign nodules get biopsied or removed.
When Biopsy or Surgery Enters the Picture
If a nodule keeps growing at a pace that could be consistent with cancer, or if imaging features remain ambiguous after serial scans, doctors often recommend a tissue sample. Two main approaches exist: navigational bronchoscopy, where a flexible scope is threaded through the airways to reach the nodule, and transthoracic needle biopsy, where a needle is passed through the chest wall under CT guidance.
A large head-to-head trial comparing the two techniques found that navigational bronchoscopy produced an accurate diagnosis in about 79% of cases, while transthoracic needle biopsy achieved accuracy in roughly 74%, meeting the bar for noninferiority. The safety profiles differed markedly, though. Pneumothorax, where air leaks into the space around the lung, occurred in about 3% of bronchoscopy patients compared with 28% of those who had needle biopsy. The rate of pneumothorax severe enough to require a chest tube or hospital admission was under 1% for bronchoscopy versus about 12% for needle biopsy.18PubMed Central. Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules
When biopsy is inconclusive or when the nodule’s location makes it hard to reach with a needle or bronchoscope, minimally invasive surgery may be the next step. Video-assisted thoracoscopic surgery (VATS) allows a surgeon to remove the nodule through small incisions, usually with short operative times and a brief hospital stay. For small peripheral nodules, techniques like CT-guided microcoil marking before VATS have been shown to achieve a diagnosis in essentially all cases.19PubMed Central. CT-guided microcoil VATS resection of lung nodules: a single-centre experience and review of the literature Newer approaches, including nonintubated VATS performed without a breathing tube, have expanded surgical options for patients who are higher risk for general anesthesia.20PubMed Central. Nonintubated video-assisted thoracoscopic surgery for management of indeterminate pulmonary nodules
The frustrating reality is that some patients go through a biopsy or even surgery only to learn the nodule was benign all along. That outcome feels like it should be avoidable, but given the consequences of missing an early-stage cancer, the medical system errs toward action when the imaging stays equivocal.
The Emotional Weight of a Nodule on Your Scan
If you have been told you have a lung nodule and need follow-up imaging, you are not alone in finding the wait stressful. In a survey of over 100 patients with pulmonary nodules, about 60% reported worrying about their nodule at least once a month, and roughly one in five worried daily. The average anxiety score was about 5 out of 10.21PubMed Central. Effect of a pulmonary nodule fact sheet on patient anxiety and knowledge: a quality improvement initiative That is a meaningful level of distress for something that, statistically, is likely benign.
A multicenter survey found that about a quarter of patients with incidental nodules experienced clinically significant distress. The biggest sources of concern were uncertainty about what caused the nodule (78% of patients), the possibility of cancer (73%), and the potential need for surgery (64%). Only about a quarter of patients accurately estimated their actual cancer risk, and perceived risk had essentially no correlation with actual risk. Patients whose doctors gave them explicit information about their cancer risk tended to find that information more reassuring than frightening.22PubMed Central. Patients’ Knowledge, Beliefs, and Distress Associated with Detection and Evaluation of Incidental Pulmonary Nodules for Cancer: Results from a Multicenter Survey
Research on physician communication styles reinforces this point. When doctors used a person-centered approach, expressing genuine interest and framing the follow-up as a partnership, patients reported lower distress not just at the initial visit but over two years of follow-up. Better communication also predicted better adherence to the recommended scan schedule.23PubMed Central. The person behind the nodule: a narrative review of the psychological impact of lung cancer screening If your doctor is not explaining your risk clearly, or if you are left to fill the silence with your own worst-case scenarios, it is worth asking directly: “Based on everything you see, what is the realistic chance this is cancer?” Most of the time, the honest answer is lower than you fear.
When “Benign” Does Not Mean “Forget About It”
Even when a nodule is confidently diagnosed as benign, there are situations where it still needs attention. A hamartoma that happens to sit near a major airway can, over years of slow growth, eventually compress the bronchus enough to cause coughing, wheezing, or recurrent infections in the blocked lung segment. Inflammatory pseudotumors, a category of benign lung mass driven by immune cell overgrowth, can present as solitary nodules or occasionally as larger masses, and some grow large enough to cause symptoms.24Elsevier / The Annals of Thoracic Surgery. Inflammatory pseudotumor of the lung in adults
Occupational nodules from silica or coal dust exposure represent a different kind of ongoing risk. The nodules themselves are fibrotic scars, not tumors, but progressive massive fibrosis, where small nodules gradually coalesce into large upper-lobe masses, can cause serious impairment of lung function. Workers with known exposure histories and early-stage nodular disease benefit from removal from further exposure and regular monitoring even though the individual nodules are benign.
Rheumatoid nodules in the lung can fluctuate with disease activity, sometimes shrinking on their own or in response to treatment of the underlying arthritis. In rare cases they can cavitate, forming a hollow center, or become infected. For patients with rheumatoid arthritis on immunosuppressive medications, any new or growing lung nodule raises a wider differential that includes drug-related lung toxicity and opportunistic infection, not just the rheumatoid disease itself. The context around the nodule often matters as much as the nodule’s behavior on a scan.